- Home
- BDTX vs IPHA Comparison
BDTX vs IPHA Comparison
Compare BDTX & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BDTX | IPHA |
|---|---|---|
| Founded | 2014 | 1999 |
| Country | United States | France |
| Employees | N/A | 174 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 140.7M | 160.7M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | BDTX | IPHA |
|---|---|---|
| Price | $2.33 | $1.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | ★ $10.40 | $5.00 |
| AVG Volume (30 Days) | ★ 597.2K | 16.0K |
| Earning Date | 03-09-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.45 | N/A |
| EPS | ★ 0.65 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $28.31 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.72 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.20 | $1.57 |
| 52 Week High | $4.94 | $2.63 |
Technical Indicators
Market Signals| Indicator | BDTX | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 42.44 | 41.28 |
| Support Level | $2.19 | $1.60 |
| Resistance Level | $2.86 | $1.90 |
| Average True Range (ATR) | 0.10 | 0.08 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 33.33 | 20.46 |
Price Performance
Historical ComparisonAbout BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.